Century Therapeutics Inc. (IPSC) Live Share Price, Invest From India

Century Therapeutics Inc. Stock Performance

as on June 27, 2026 at 2:16 pm IST

Day's Low
Day's High
$2.27
Day's Price Range
$2.50
$2.32
2.16%
Downside
7.76%
Upside
52 Week's Low
52 Week's High
$0.44
52-Week Price Range
$3.04
$2.32
81.25%
Downside
31.03%
Upside

Century Therapeutics Inc. share price movements today

Previous Close: $2.30
Open: $2.28
Volume: 2.9M
Day's Low - High: $2.27 - $2.50
52 Week Low - High: $0.44 - $3.04

Century Therapeutics Inc. Historical Returns

1 Month Return: + 5.99 %
3 Month Return: + 11.65 %
1 Year Return: + 305.21 %
3 Year Return: -32.35 %
5 Year Return: 0 %

Century Therapeutics Inc. Stock Fundamentals & Key Indicators

Check Century Therapeutics Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$413.0M

EPS (TTM)

-0.46

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

EBITDA

-101.6M

Revenue (TTM)

Profit Margin

0.00%

Return On Equity TTM

-42.67%

Century Therapeutics Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Century Therapeutics Inc. with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %	Dividend Yield %
Century Therapeutics Inc.	BUY	$413.0M	NA	NA	0.00%	NA
Alnylam Pharmaceuticals Inc.	BUY	$39.3B	67.15%	74.07	12.55%	NA
Vertex Pharmaceuticals Inc.	BUY	$120.6B	147.08%	28.17	35.51%	NA
Regeneron Pharmaceuticals Inc.	BUY	$65.4B	12.64%	15.22	29.65%	0.58%

Stock Returns calculator for Century Therapeutics Inc. Stock including INR - Dollar returns

The Century Therapeutics Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

Century Therapeutics Inc. investment value today

Current value as on today

₹4,47,862

Returns

₹3,47,862

(+347.86%)

Returns from Century Therapeutics Inc. Stock

₹3,07,018 (+307.02%)

Dollar Impact

₹40,844 (+40.84%)

Analyst Recommendation on Century Therapeutics Inc. Stock

Based on 13 analysts

BUY

84.62%

Buy

15.38%

Hold

0.00%

Sell

Based on 13 analysts, 84.62% of analysts recommend a 'BUY' rating for Century Therapeutics Inc.. Average target price of $4.75

Century Therapeutics Inc. Share Price Target

Get share price movements and forecasts by analysts on Century Therapeutics Inc..

What analysts predicted

51.16%UPSIDE

Target Price

$4.75

Current Price

$2.32

Analyzed by

13 Analysts

Target

$4.75

Century Therapeutics Inc. target price $4.75, a slight upside of 51.16% compared to current price of $2.32. According to 13 analysts rating.

Indian Investors' Interest in Century Therapeutics Inc. Stock

Search interest for Century Therapeutics Inc. Stock has decreased by -50% in the last 30 days, reflecting a downward trend in search activity.

Time period: May 30, 2026 to June 29, 2026

Change:-50% versus previous 30 day period

Century Therapeutics Inc. Quarterly Profit & Loss

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Revenue	0	0	0	0	4	109	-	-	-	-
Gross Profit	-22	0	0	0	4	109	-26	-3	-3	-3
Operating Income	-43	-31	-34	-34	-37	74	-34	-36	-20	-25
EBITDA	-27	-24	-27	-27	-30	79	-29	-26	-15	-18
Interest Expense	1	-	-	-	-	-	-	-	-	-
Depreciation	3	3	3	3	3	3	3	3	3	3
Income Before Tax	-40	-28	-31	-31	-34	76	-32	-34	-19	-21
Income Tax Expense	0	0	0	0	1	-	-	-	0	-
Net Income	-39	-28	-31	-31	-36	76	-32	-34	-19	-21
Net Profit Margin	-14700.75%	-3282.11%	-4047.60%	-3947.66%	-864.44%	70.13%	0.00%	0.00%	0.00%	0.00%

Century Therapeutics Inc. Annual Profit & Loss

All numbers in Millions USD

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	-	-	1	5	2	6	109
Gross Profit	0	-1	-4	5	2	6	96
Operating Income	-20	-49	-94	-133	-146	-138	-15
EBITDA	-244	-51	-89	-121	-121	-111	3
Interest Expense	-	0	1	1	0	-	-
Depreciation	0	1	3	8	12	13	13
Income Before Tax	-244	-53	-95	-130	-134	-124	-9
Income Tax Expense	1	1	0	0	1	1	0
Net Income	-244	-53	-95	-130	-136	-126	-9
Net Profit Margin	0.00%	0.00%	-9057.09%	-2518.41%	-6115.12%	-1920.87%	-8.78%

Century Therapeutics Inc. Quarterly Cash Flow

All numbers in Millions USD

	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Net Income	-28	-31	-31	-36	76	-32	-34	-19	-21
Operating Cash Flow	-30	-27	-28	-24	-34	-27	-25	-16	-25
Investing Cash Flow	11	-33	39	30	27	32	24	22	-112
Financing Cash Flow	18	56	0	0	0	-	-	0	126
Change in Cash	0	-4	11	5	-6	4	0	6	-11

Century Therapeutics Inc. Annual Cash Flow

All numbers in Millions USD

	Dec 2016	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-	-244	-53	-95	-130	-136	-126	-9
Operating Cash Flow	-	-16	-41	-89	14	-88	-110	-103
Investing Cash Flow	-	-19	-22	-298	-13	61	47	107
Financing Cash Flow	98	74	47	417	27	-9	74	0
Change in Cash	-	38	-16	30	28	-36	11	3

Global Institutional Holdings in Century Therapeutics Inc.

Funds	Holdings
Geode Capital Management, LLC	0.72%
Two Sigma Investments LLC	1.31%
Versant Venture Management LLC	6.75%
Two Sigma Advisers, LLC	0.7%
Casdin Capital, LLC	0.68%

See all

Insights on Century Therapeutics Inc.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Price Rise
In the last 6 months, IPSC stock has moved up by 113.8%
POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 4 quarters, 771.0K → 109.16M (in $), with an average increase of 59.9% per quarter
POSITIVE IMPACT
Best in 1 Year
In the last 1 year, IPSC has outperformed top 5 stocks with highest market-cap in its industry
NO EFFECT
Against Peers
In the last 3 years, Century Therapeutics, Inc. Common Stock has experienced a drawdown of -26.3%, however Alnylam Pharmaceuticals, Inc. Common Stock resisted the overall trend and outperformed by 16.7%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -19.17M → -21.64M (in $), with an average decrease of 12.9% per quarter

About Century Therapeutics Inc.

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Organisation	Century Therapeutics Inc.
Headquarters	25 North 38th Street, Philadelphia, PA, United States, 19104
Industry	Biotechnology
CEO	Dr. Brent Pfeiffenberger M.B.A., Pharm.D.
E-voting on shares	Click here to vote

Key Management of Century Therapeutics Inc.

Name	Title
Dr. Chad A. Cowan Ph.D.	Chief Scientific Officer
Mr. Douglas Carr CPA	Senior VP of Finance & Operations, Principal Financial Officer and Secretary
Krista Kauppinen J.D., Ph.D.	VP, General Counsel & Head of Intellectual Property
Ms. Megan Bilson	Chief People Officer
Michael Naso Ph.D.	Senior VP of Cell Engineering
Ms. Elizabeth Devlin	VP & Head of Development
Dr. Brent Pfeiffenberger M.B.A., Pharm.D.	President, CEO & Chairman
Dr. Gregory Russotti Ph.D.	Chief Technology & Manufacturing Officer

FAQs

What is Century Therapeutics Inc. share price today?

Century Therapeutics Inc. share price today is $2.32 as on June 27, 2026 at 8:46 am IST at the close of the market. Century Therapeutics Inc. share today touched a day high of $2.5 and a low of $2.27.

What is the 52 week high and 52 week low for Century Therapeutics Inc. share?

Century Therapeutics Inc. share touched a 52 week high of $3.04 on March 10, 2026 and a 52 week low of $0.44 on November 17, 2025. Century Therapeutics Inc. stock price today i.e. June 27, 2026 at 8:46 am IST is closed at $2.32,which is 23.68% down from its 52 week high and 433.33% up from its 52 week low.

What is Century Therapeutics Inc.'s market capitalisation today?

Century Therapeutics Inc. market capitalisation is $0.00T as on June 27, 2026 at 8:46 am IST.

How to invest in Century Therapeutics Inc. Stock (IPSC) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Century Therapeutics Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Century Therapeutics Inc. Shares that will get you 0.6466 shares as per Century Therapeutics Inc. share price of $2.32 per share as on June 27, 2026 at 8:46 am IST.

What is the minimum amount required to buy Century Therapeutics Inc. Stock (IPSC) from India?

Indian investors can start investing in Century Therapeutics Inc. (IPSC) shares with as little as ₹94.3 or $1 (as of June 29, 2026 at 3:00 am IST) using the INDmoney app.
For example: If you want to invest $10 or ₹943.00 in Century Therapeutics Inc. stock (as per the Rupee-Dollar exchange rate as on June 29, 2026 at 3:00 am IST). Based on Century Therapeutics Inc. share’s latest price of $2.32 as on June 27, 2026 at 8:46 am IST, you will get 4.3103 shares of Century Therapeutics Inc.. Learn more about fractional shares .